Imeglimin治疗2型糖尿病的研究进展

Imeglimin in the treatment of type 2 diabetes mellitus

Imeglimin是一种正在研究的新型口服降糖药物,靶向作用于细胞线粒体,通过改善胰岛素抵抗、抑制糖异生及保护β细胞功能等作用而发挥独特的降糖机制。目前在日本进行的临床试验表明,无论是作为单药或是与其他降糖药物联用,imeglimin对2型糖尿病均显示出较好的降糖作用且耐受性良好。Imeglimin作为具有特殊机制的降糖药物,有望成为2型糖尿病新的治疗选择。

Imeglimin is an investigational first-in-class novel anti-diabetic agent,which targets on the mitochondria of cells and plays a unique hypoglycemic mechanism by improving insulin resistance,inhibiting gluconeogenesis and protecting beta-cell function to reduce blood glucose.The current clinical trials conducted in Japan show that imeglimin is effective and well tolerated in type 2 diabetic patients either as a single drug or in combination with other anti-diabetic compounds.As a distinct anti-diabetic agent,imeglimin is expected to be a new therapeutic option for type 2 diabetes.